Literature DB >> 17943971

FLT3 mutations in a 10 year consecutive series of 177 childhood acute leukemias and their impact on global gene expression patterns.

Anna Andersson1, Kajsa Paulsson, Henrik Lilljebjörn, Carin Lassen, Bodil Strömbeck, Jesper Heldrup, Mikael Behrendtz, Bertil Johansson, Thoas Fioretos.   

Abstract

During 1995-2004, 209 children/adolescents were diagnosed with acute lymphoblastic or myeloid leukemia (ALL, AML) in Southern Sweden, of which 177 (85%), comprising 128 B-lineage ALL, 34 AML, and 15 T-cell ALL, could be analyzed for internal tandem duplications (ITD) and activating point mutations in the second tyrosine kinase domain (ATKD) of FLT3. Seventeen (10%) FLT3 mutations (6 ITD, 11 ATKD; mutually exclusive) were detected. None of the T-cell ALL harbored any mutations. ITD and ATKD were found in 2% and 6% of the B-lineage ALL and in 12% and 9% of the AML, being particularly common in high hyperdiploid ALL (14%), ALL (20%), and AML (23%) with 11q23/MLL rearrangements, and in AML with a normal karyotype (60%). All ATKD-positive AML with MLL rearrangements harbored the t(9;11)(p21;q23). Global gene expression data were available for 76 of the B-lineage ALL and 19 of the AML, of which 6 (8%) and 3 (16%) had FLT3 mutations, respectively. No distinct expression pattern associated with FLT3 mutations was identified.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17943971     DOI: 10.1002/gcc.20508

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

1.  Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children.

Authors:  Adam J de Smith; Geneviève Lavoie; Kyle M Walsh; Sumeet Aujla; Erica Evans; Helen M Hansen; Ivan Smirnov; Alice Y Kang; Martin Zenker; John J Ceremsak; Elliot Stieglitz; Ivo S Muskens; William Roberts; Roberta McKean-Cowdin; Catherine Metayer; Philippe P Roux; Joseph L Wiemels
Journal:  Genes Chromosomes Cancer       Date:  2019-05-27       Impact factor: 5.006

Review 2.  Global characteristics of childhood acute promyelocytic leukemia.

Authors:  L Zhang; A Samad; M S Pombo-de-Oliveira; G Scelo; M T Smith; J Feusner; J L Wiemels; C Metayer
Journal:  Blood Rev       Date:  2014-09-30       Impact factor: 8.250

3.  FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia.

Authors:  Patrick Chang; Michelle Kang; Anny Xiao; Jeffrey Chang; James Feusner; Patricia Buffler; Joseph Wiemels
Journal:  BMC Cancer       Date:  2010-09-27       Impact factor: 4.430

4.  Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia.

Authors:  M Braoudaki; M Karpusas; K Katsibardi; Ch Papathanassiou; K Karamolegou; F Tzortzatou-Stathopoulou
Journal:  Med Oncol       Date:  2008-12-16       Impact factor: 3.064

5.  FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical Significance.

Authors:  Ghaleb Elyamany; Mohammed Awad; Omar Alsuhaibani; Kamal Fadalla; Omer Al Sharif; Mohammad Al Shahrani; Fahad Alabbas; Abdulaziz Al-Abulaaly
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-06-01       Impact factor: 2.576

6.  FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia.

Authors:  Albert Català; Marçal Pastor-Anglada; Liska Caviedes-Cárdenas; Roberta Malatesta; Susana Rives; Nerea Vega-García; Mireia Camós; Paula Fernández-Calotti
Journal:  Oncotarget       Date:  2016-08-02

7.  FLT3N676K drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesis.

Authors:  Axel Hyrenius-Wittsten; Mattias Pilheden; Antoni Falqués-Costa; Mia Eriksson; Helena Sturesson; Pauline Schneider; Priscilla Wander; Cristian Garcia-Ruiz; Jian Liu; Helena Ågerstam; Anne Hultquist; Henrik Lilljebjörn; Ronald W Stam; Marcus Järås; Anna K Hagström-Andersson
Journal:  Leukemia       Date:  2019-04-05       Impact factor: 11.528

Review 8.  Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting.

Authors:  Thomas Knight; Julie Anne Elizabeth Irving
Journal:  Front Oncol       Date:  2014-06-24       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.